Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
Globe Newswire•26/10/2026•07:30 ET
0
Key Highlights
- ➤Phase 3 MAPKeeper 301 evaluates atebimetinib plus modified chemotherapy in first-line metastatic pancreatic cancer
- ➤Phase 2a median overall survival reached 17.3 months among 55 patients
- ➤Phase 2a progression-free survival was 8.3 months
- ➤Phase 3 trial began dosing in June 2026 and is currently recruiting
- ➤Overall survival is MAPKeeper 301’s primary endpoint
Expert Statements
Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering
“Pancreatic cancer remains one of the most difficult cancers to treat, and patients with metastatic disease in the first-line setting urgently need new therapies capable of delivering meaningful improvements in survival.”
Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering
“Our encouraging Phase 2a results reported at ASCO, including median overall survival of 17.3 months in first-line pancreatic cancer patients, provide a strong foundation for MAPKeeper 301.”
Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering
“This pivotal Phase 3 trial is designed to determine whether atebimetinib, in combination with modified chemotherapy, can extend survival compared with the current standard of care.”
Ben Zeskind, Co-founder and Chief Executive Officer of Immuneering
“We believe atebimetinib’s differentiated Deep Cyclic Inhibition mechanism, designed to shrink tumors durably, preserve body mass, and minimize side effects, has the potential to transform the treatment of metastatic pancreatic cancer.”
- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -
-MAPKeeper 301 builds on encouraging Phase 2a results presented at ASCO 2026 including median overall survival (OS) of 17.3 months -
Get started
Create a free account to read the full story.